13F Holdings
中文EN

PTGX Protagonist Therapeutics, Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1377121 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY163.7%
TTM net income YoY645.5%
TTM EPS YoY616.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin58.6%
Net margin62.0%
FCF margin19.8%
EBITDA margin58.9%

Returns

ROE39.6%
ROA37.0%
ROIC (approx.)56.5%
Asset turnover0.60x

Leverage & solvency

Liabilities / assets5.4%
Debt / equity0.00x
Current ratio19.85x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.32x
Accruals ratio25.1%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$46.02M$434.43M$60.00M$26.58M$27.36M
R&D expense$159.29M$138.13M$120.16M$126.22M$126.01M
SG&A expense$44.85M$43.46M$33.49M$31.74M$27.20M
Operating income-$158.13M$252.84M-$93.65M-$131.37M-$125.84M
Pretax income-$129.31M$279.41M-$78.95M-$127.39M-$125.55M
Income tax$838,000$4.22M$0$0$0
Net income-$130.15M$275.19M-$78.95M-$127.39M-$125.55M
EBITDA-$156.85M$253.67M-$92.67M-$130.34M-$125.03M
EPS (basic)-2.054.47-1.39-2.60-2.71
EPS (diluted)-2.054.23-1.39-2.60-2.71
Weighted avg. shares (diluted)63.57M65.08M56.76M49.04M46.32M
Balance sheet
Cash & equivalents$128.39M$97.47M$186.73M$125.97M$123.89M
Short-term investments$438.97M$321.66M$154.89M$111.61M$203.24M
Current assets$577.57M$591.64M$355.58M$243.08M$340.74M
PP&E, net$3.86M$3.19M$1.20M$1.56M$1.80M
Total assets$668.19M$744.73M$357.95M$247.93M$347.69M
Current liabilities$45.44M$47.40M$21.27M$31.18M$44.02M
Total liabilities$53.48M$69.43M$21.27M$32.32M$47.67M
Shareholders' equity$614.71M$675.29M$336.68M$215.61M$300.02M
Shares outstanding62.58M61.04M57.71M49.34M47.84M
Cash flow statement
Operating cash flow$57.67M$184.15M-$70.24M-$108.14M-$107.86M
Capital expenditure$1.59M$1.35M$609,000$795,000$1.10M
Free cash flow$56.08M$182.80M-$70.84M-$108.93M-$108.97M
Investing cash flow-$49.33M-$299.48M-$39.26M$91.47M-$15.86M
Financing cash flow$22.86M$25.85M$170.48M$18.84M$129.92M
Depreciation & amortization$1.28M$826,000$977,000$1.03M$813,000
Stock-based compensation$45.97M$37.55M$29.29M$24.20M$16.39M

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.